title: Lung injury linked to etanercept therapy.
abstract: Etanercept is the first anticytokine drug approved to treat rheumatoid arthritis. Side effects are infrequent, the most common being local skin reactions, headaches, and upper respiratory tract symptoms. We report the first case of lung injury that occurred while receiving this agent. Biopsy specimens of lung and skin lesions demonstrated noncaseating granulomas associated with a microscopic particulate. Withdrawal of etanercept achieved clinical stabilization, and the addition of prednisone resulted in rapid improvement.
authors.affiliation: WellStar Marietta Pulmonary Medicine, Marietta, GA 30060, USA. laura.peno-green@wellstar.org
authors.forename: Laura
authors.initials: L
authors.lastname: Peno-Green
authors.forename: Geronomo
authors.initials: G
authors.lastname: Lluberas
authors.forename: Thomas
authors.initials: T
authors.lastname: Kingsley
authors.forename: Steven
authors.initials: S
authors.lastname: Brantley
mesh_terms: D018501:Antirheumatic Agents / Q000009:adverse effects*; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects*; D008171:Lung Diseases / Q000139:chemically induced*; D008875:Middle Aged; D018124:Receptors, Tumor Necrosis Factor
chemical_list: D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept